Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are highly expressed in nasopharyngeal carcinoma; therefore, blocking the binding of VEGF and VEGFR may be a potential way to treat nasopharyngeal carcinoma. Apatinib inhibits tumor angiogenesis. Previous studies have suggested that treatment with apatinib has an antitumor effect on nasopharyngeal carcinoma. This study will investigate the effect of apatinib combined with radiotherapy. In this study, nude mice injected with CNE-2 nasopharyngeal carcinoma cells were randomly divided into 6 groups. Therapeutic effects were assessed by evaluating tumor inhibition rate, phosphorylation of VEGFR-2, CD31, partial oxygen pressure, and tumor metabolism. We found that the tumor inhibition of mice in the treated groups was better compared to that of the control group. In mice treated with apatinib alone, angiogenesis was prevented, and the tumor tissue partial oxygen pressure was reduced, thereby achieving an antitumor effect. Moreover, the tumor inhibitory effect of combined treatment was stronger than treatment with either apatinib or radiotherapy alone. Compared with monotherapy treatment, combined treatment better resisted angiogenesis. Apatinib combined with radiotherapy to treat nasopharyngeal carcinoma has synergistic effects, which may be related to enhanced antiangiogenesis.

中文翻译：

---

阿帕替尼联合放疗可增强体内鼻咽癌模型的抗肿瘤作用。

血管内皮生长因子（VEGF）及其受体（VEGFR）在鼻咽癌中高表达。因此，阻断VEGF和VEGFR的结合可能是治疗鼻咽癌的一种潜在方法。阿帕替尼抑制肿瘤血管生成。先前的研究表明，阿帕替尼治疗对鼻咽癌具有抗肿瘤作用。这项研究将调查阿帕替尼联合放疗的疗效。在这项研究中，将注射CNE-2鼻咽癌细胞的裸鼠随机分为6组。通过评估肿瘤抑制率，VEGFR-2的磷酸化，CD31，部分氧压和肿瘤代谢来评估治疗效果。我们发现，与对照组相比，治疗组对小鼠的肿瘤抑制作用更好。在单独用阿帕替尼治疗的小鼠中，防止了血管生成，并且降低了肿瘤组织的部分氧压，从而实现了抗肿瘤作用。而且，联合治疗的肿瘤抑制作用比单独使用阿帕替尼或放疗的治疗更强。与单一疗法相比，联合疗法更好地抵抗血管生成。阿帕替尼联合放疗治疗鼻咽癌具有协同作用，可能与抗血管生成增强有关。联合治疗更好地抵抗血管生成。阿帕替尼联合放疗治疗鼻咽癌具有协同作用，可能与抗血管生成增强有关。联合治疗更好地抵抗血管生成。阿帕替尼联合放疗治疗鼻咽癌具有协同作用，可能与抗血管生成增强有关。